Download the MIMS Education app now!
Metronomic Chemotherapy in Metastatic Breast Cancer Treatment
RadiologyOncology
CME Unit: 0.50/1 point | 
48 minutes | 
07 Mar 2027
Overview
About this course
This e-learning module explores personalised treatment in metastatic breast cancer, highlighting the role of oral agents. It focuses on low-dose metronomic chemotherapy and its efficacy, low toxicity, and quality-of-life benefits. Clinical evidence is presented supporting the benefits of metronomic regimens compared with traditional intravenous approaches in specific patient profiles.
Learning outcomes
Upon completion of the educational activity, health care providers should be able to:
- Understand the role of personalised treatment and metronomic chemotherapy in the management of metastatic breast cancer
- Compare the benefits of oral metronomic regimens with traditional intravenous chemotherapy
- Identify suitable patient profiles for metronomic chemotherapy
- Explore emerging directions in metronomic chemotherapy, including biomarker-driven patient selection and combination therapies
Topics covered:
- European Society for Medical Oncology (ESMO) guidelines
- American Society of Clinical Oncology (ASCO) guidelines & metronomic use
- Importance of personalised treatment
- Ideal patients for oral chemotherapy
- The HERMIONE-13 study
- The future of oral vinorelbine
0.50/1 CME Point Available
- This module is accredited for 1 CME point for fellows of The Hong Kong College of Pathologists and Hong Kong College of Radiologists, and 0.5 CME point for fellows of the Hong Kong College of Physicians.
- Please note that this module will not earn CME credit for fellows of colleges not listed here.
- A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME point(s).
Supported by:
Something went wrong.